CN103055164B - Traditional Chinese medicine composition for treating isolated diastolic hypertension - Google Patents

Abstract

The invention discloses a traditional Chinese medicine composition for treating isolated diastolic hypertension. The traditional Chinese medicine composition is composed of uncaria, raw eucommia, Chinese taxillus herb, cyathula root and tall gastrodia tuber. Conventional adjuvants are added into the above-mentioned raw materials, and a conventional process is utilized for preparation of a tablet, a capsule, a powder, a soft capsule, etc. The traditional Chinese medicine composition has a substantial therapeutic effect on isolated diastolic hypertension and has no side-effects.

Description

A traditional Chinese medicine composition for treating simple diastolic hypertension

technical field

The invention relates to a traditional Chinese medicine composition, in particular to a traditional Chinese medicine composition for treating simple diastolic hypertension. the

Background technique

Isolated diastolic hypertension (IDH) refers to hypertension with systolic blood pressure (SBP) < 140 mmHg and diastolic blood pressure (DBP) ≥ 90 mmHg, which is a subtype of hypertension. The study found that systolic blood pressure rises with age, while diastolic blood pressure reaches a peak around 60 years old for men and 70 years old for women, and then slowly declines. Therefore, the proportion of isolated systolic hypertension (ISH) increased significantly and the proportion of isolated diastolic hypertension decreased significantly with age. the

IDH is most likely to occur in the young, male, obese, and sleep-disordered persons, especially those with unhealthy living habits such as smoking, alcoholism, and lack of exercise. the

Many studies have confirmed that both systolic and diastolic blood pressure are independent risk factors for stroke and coronary heart disease. A prospective observational study conducted on 420,000 people in the United Kingdom proved that there is a very clear linear correlation between diastolic blood pressure and stroke. Even within the normal range, there is a clear positive correlation between diastolic blood pressure and stroke. The incidence of coronary heart disease increased by 56%, and the incidence of coronary heart disease increased by 37%. Therefore, the hazards of diastolic hypertension should not be underestimated. the

Contents of the invention

The invention provides a traditional Chinese medicine composition for treating simple diastolic hypertension. the

The object of the invention is achieved through the following technical solutions:

Chinese medicine composition crude drug of the present invention consists of:

5-30 parts by weight of Uncaria 5-15 parts by weight of Eucommia ulmoides 5-15 parts by weight of Sangjisi 5-20 parts by weight of Chuan Achyranthes bidentata 1-15 parts by weight of Gastrodia elata

The composition of the Chinese medicine composition raw material of the present invention is preferably:

15-30 parts by weight of Uncaria 10-15 parts by weight of Eucommia ulmoides 8-12 parts by weight of Sangjisi 10-15 parts by weight of Achyranthes sichuanensis Gastrodia 5-10 parts by weight

The composition of the Chinese medicine composition raw material of the present invention is preferably:

12 parts by weight of Uncaria, 10 parts by weight of Eucommia ulmoides, 10 parts by weight of Sangjisheng, 12 parts by weight of Achyranthes bidentata, 8 parts by weight of Gastrodia elata

The composition of the Chinese medicine composition raw material of the present invention is preferably:

Uncaria 14 parts by weight Raw Eucommia 9 parts by weight Sangjisi 9 parts by weight Achyranthes bidentata 14 parts by weight Gastrodia elata 6 parts by weight

The composition of the Chinese medicine composition raw material of the present invention is preferably:

11 parts by weight of Uncaria, 11 parts by weight of Eucommia ulmoides, 11 parts by weight of Sangjisheng, 12 parts by weight of Achyranthes sichuanensis, 8 parts by weight of Gastrodia elata

The traditional Chinese medicine composition of the present invention is added conventional adjuvant materials, according to the conventional process, is made into tablet, capsule, powder, soft capsule, dripping pill, honeyed pill, pill, granule, honey refining ointment, slow-release preparation, quick-release preparation, Controlled-release preparations, oral liquid preparations, lyophilized powder preparations or injection preparations. the

The traditional Chinese medicine composition of the present invention is composed of Eucommia ulmoides, Sangjisheng, Achyranthes bidentata, Gastrodia elata and Uncaria. Eucommia ulmoides is good at invigorating the liver and kidney, strengthening the bones and muscles to cure the root cause, and is the king medicine. The subject is Sangjisheng, which mainly enters the liver and kidney meridians, and its function is to nourish the liver and kidney, so as to increase the power of the monarch medicine; the combination of the two medicines is especially suitable for patients with weak waist and knees, tinnitus and forgetfulness of liver and kidney deficiency hypertension. Uncaria, the function of calming liver yang, is also a ministerial drug, and is the main drug for treating headache and dizziness due to hyperactivity of liver yang. Accompanied by Chuan Achyranthes bidentata, one is to nourish the liver and kidney, and the other is to guide the hyperactive liver-yang to descend, and treat both the symptoms and root causes; Gastrodia elata calms the liver-yang to treat the symptoms, and it is also a meridian-leading medicine for headaches. Combination of various medicines can treat both symptoms and root causes, harmonize yin and yang, and can stably lower blood pressure. the

The traditional Chinese medicine composition of the invention has remarkable effect in treating hypertension in simple diastolic period and has no side effect. the

The following experiments and examples are used to further illustrate but not limit the present invention. the

Experimental Example 1: Clinical Experiment

1 Materials and methods

1.1 General Information

All the cases were from outpatients and inpatients of Guangzhou Liwan District Hospital of Traditional Chinese Medicine and Guangzhou Hospital of Traditional Chinese Medicine from December 2003 to October 2006. A total of 90 patients with isolated diastolic hypertension were included according to the diagnostic criteria, inclusion criteria, and exclusion criteria. According to the random number method, they were randomly divided into the experimental group and the control group. The test group consisted of 67 cases, including 22 males and 45 females, aged 64.42±12.43 years, and the course of disease was 4.60±4.92 years. The control group consisted of 30 cases, including 17 males and 13 females, aged 74.13±10.00 years old, and the course of disease was 7.18±5.81 years. There was no significant difference between the two groups of data after statistical processing (p>0.05), and they were comparable. the

1.2 Interventions

The test group took the traditional Chinese medicine composition of the present invention (prepared according to Example 2), 120ml each time, twice a day, with warm water. The control group took Yinarin (enalapril maleate tablets, 20 mg per tablet), 20 mg each time, twice a day, and took it with warm water half an hour after meals. The course of treatment for both groups was 1 month. the

During the treatment period, the patients in the two groups were given a low-salt and low-fat diet, stopped using other antihypertensive, lipid-lowering and blood pressure-affecting drugs, adjusted their spirits, exercised appropriately, and avoided fatigue. the

1.3 Observation indicators

1.3.1 Efficacy indicators: blood pressure, renin activity (PRA), angiotensin II (AII), aldosterone (ALD), hemorrheology, liver function, and blood lipids. the

1.3.2 Safety indicators: blood routine, urine routine, adverse reactions. the

1.4 Statistical methods

SAS8.2 statistical software was used for analysis, grade data was tested by Wilcoxon, count data was tested by ^X2 , and measurement data was tested by t test.

2 Results

2.1 Comparison of the total effective rate of blood pressure reduction in the two groups

In the test group, the effective rate of reducing blood pressure was 86.57%, the effective rate was 11.94%, and the total effective rate was 95.52%. The obvious rate of antihypertensive in the control group was 80%, the effective rate was 20%, and the total effective rate was 100%. There was no significant difference in antihypertensive effect between the two groups, as shown in Table 1. the

Table 1 Comparison of effective rates of lowering blood pressure between the two groups (cases %)

Note: There was no significant difference in curative effect between the two groups (p>0.05). the

2.2 Comparison of hemorheological curative effect between the two groups

There was no significant difference in hemorheology values between the two groups before treatment, see Table 2 for details. After treatment, the plasma viscosity of the experimental group was significantly reduced, and there was a statistical difference (p<0.05); there was no statistical difference in hemorheology between the two groups after treatment (p>0.05), see Table 3 for details. the

Table 2 Comparison of hemorheology values between the two groups before treatment

Note: There was no significant difference in the values of blood rheology between the two groups before treatment, and they were comparable (p>0.05). the

Table 3 Comparison of curative effect of hemorheology within and between groups after treatment between the two groups

Note: It can be seen from Table 3 that the plasma viscosity of the experimental group decreased significantly after treatment (p<0.05), and there was no significant difference between the two groups (p>0.05). the

2.3 Comparison of curative effect of improving blood lipids between the two groups

There was no significant difference in blood lipid values between the two groups before treatment, see Table 4 for details. Cholesterol, triglycerides, and low-density lipoproteins in the control group were significantly reduced after treatment, and high-density lipoproteins in the test group were significantly increased, but there was no significant difference between the two groups (p>0.05), as shown in the table 5. the

Table 4 Comparison of blood lipid values between the two groups before treatment

Note: There was no significant difference in blood lipid values between the two groups before treatment, and they were comparable (p>0.05). the

Table 5 Comparison of curative effect of blood lipid improvement within and between groups after treatment between the two groups

Note: Cholesterol, triglycerides, and low-density lipoproteins in the control group were significantly reduced after treatment, and high-density lipoproteins in the test group were significantly increased, but there was no significant difference between the two groups (p>0.05). the

2.4 Comparison of the curative effect of improving the three items of hypertension (PRA, AⅡ, ALD) between the two groups

There was no significant difference in the values of PRA, AⅡ, and ALD between the two groups before treatment, and they were comparable (p>0.05). See Table 6 for details. After treatment, the content of angiotensin Ⅱ (AⅡ) in the experimental group decreased significantly (p<0.01), and there was no significant difference between the two groups in PRA, AⅡ, and ALD (p>0.05). See Table 7 for details. the

Table 6 Comparison of the three values of hypertension between the two groups before treatment

Note: There was no significant difference in the three values of hypertension between the two groups before treatment, and they were comparable (p>0.05). the

Table 7 Comparison of curative effect within and between groups of the three values of hypertension after treatment in the two groups

Note: The content of angiotensin Ⅱ (AⅡ) in the experimental group decreased significantly after treatment (p<0.01), and there was no significant difference between the two groups in PRA, AⅡ, and ALD (p>0.05). the

2.5 Security Analysis

2.5.1 Comparison of the effects of the two groups on liver function

There was no significant difference in liver function values between the two groups before treatment, see Table 8 for details. After treatment, ALT, TBIL, and IBIL in the experimental group were significantly reduced (p<0.05), and there was no significant difference compared with the control group (p>0.05). See Table 9 for details. the

Table 8 Comparison of liver function values between the two groups before treatment

Note: There was no significant difference in liver function values between the two groups before treatment, and they were comparable (p>0.05). the

Table 9 Comparison of curative effect on liver function within and between groups after treatment between the two groups

Note: After treatment, ALT, TBIL, and IBIL in the experimental group decreased significantly (p<0.05), and there was no significant difference compared with the western medicine group (p>0.05). the

2.5.2 Observation of adverse reactions

There was no significant change in blood and urine routine tests before and after treatment in the two groups; no obvious adverse reactions were found in the two groups. the

The following embodiments can all realize the effects of the above-mentioned experimental examples. the

Embodiment one:

Uncaria 12g Raw Eucommia 10g Sangjisi 10g Sichuan Achyranthes bidentata 12g Gastrodia elata 8g

The above-mentioned medicines are prepared into tablets by adding conventional auxiliary materials according to conventional processes. the

Embodiment two:

Uncaria 15g Raw Eucommia 10g Sangjisi 10g Sichuan Achyranthes bidentata 15g Gastrodia elata 10g

The above-mentioned medicine is prepared into an oral liquid by adding conventional auxiliary materials according to a conventional process. the

Embodiment three:

Uncaria 11g Raw Eucommia 11g Sangjisi 11g Sichuan Achyranthes bidentata 12g Gastrodia elata 8g

The above-mentioned medicines are prepared into granules by adding conventional auxiliary materials according to a conventional process. the

Embodiment four:

Uncaria 6g Raw Eucommia 13g Sangjisi 14g Sichuan Achyranthes bidentata 6g Gastrodia elata 13g

The above-mentioned drugs are made into injection preparations by adding conventional excipients according to conventional processes. the

Embodiment five:

Uncaria 18g Raw Eucommia 7g Sangjisi 7g Sichuan Achyranthes bidentata 18g Gastrodia elata 13g

The above-mentioned drugs are made into sustained-release preparations by adding conventional excipients according to conventional processes. the

Claims (17)

1. a Chinese medicine composition for the treatment of simple diastolic hypertension, characterized in that the Chinese medicine composition crude drug consists of: 5-30 parts by weight of Uncaria 5-15 parts by weight of Eucommia ulmoides 5-15 parts by weight of Sangjisi Achyranthes bidentata 5-20 parts by weight Gastrodia elata 1-15 parts by weight. 2. a kind of Chinese medicine composition for the treatment of simple diastolic hypertension as claimed in claim 1, is characterized in that this Chinese medicine composition crude drug consists of: 15-30 parts by weight of Uncaria 10-15 parts by weight of Eucommia ulmoides 8-12 parts by weight of Sangjisi Achyranthes bidentata 10-15 parts by weight Gastrodia elata 5-10 parts by weight. 3. a kind of Chinese medicine composition for the treatment of simple diastolic hypertension as claimed in claim 1, is characterized in that this Chinese medicine composition crude drug consists of: 12 parts by weight of Uncaria 10 parts by weight of Eucommia ulmoides 10 parts by weight of Mulberry Sichuan Achyranthes bidentata 12 parts by weight Gastrodia elata 8 parts by weight. 4. a kind of Chinese medicine composition for the treatment of simple diastolic hypertension as claimed in claim 1, is characterized in that this Chinese medicine composition crude drug consists of: 14 parts by weight of Uncaria, 9 parts by weight of Eucommia ulmoides, 9 parts by weight of Sangjisi Sichuan Achyranthes bidentata 14 parts by weight Gastrodia elata 6 parts by weight. 5. a kind of Chinese medicine composition for the treatment of simple diastolic hypertension as claimed in claim 1, is characterized in that this Chinese medicine composition crude drug consists of: Uncaria 11 parts by weight, Eucommia ulmoides 11 parts by weight, Sangjisheng 11 parts by weight Sichuan Achyranthes bidentata 12 parts by weight Gastrodia elata 8 parts by weight. 6. the Chinese medicine composition for the treatment of simple diastolic hypertension as described in any one of claim 1-5, it is characterized in that this Chinese medicine composition adds conventional adjuvant, according to conventional technology, makes tablet, capsule, powder, pill , granules, honey refining ointment, controlled release preparation, oral liquid preparation or injection preparation. 7. the Chinese medicinal composition for the treatment of isolated diastolic hypertension as claimed in claim 6, characterized in that said capsule is a soft capsule. 8. The Chinese medicine composition for the treatment of isolated diastolic hypertension as claimed in claim 6, characterized in that said pills are dripping pills or honeyed pills. 9. The Chinese medicinal composition for treating isolated diastolic hypertension as claimed in claim 6, characterized in that said controlled-release preparation is a sustained-release preparation or an immediate-release preparation. 10. The traditional Chinese medicine composition for treating isolated diastolic hypertension as claimed in claim 6, characterized in that said injection preparation is freeze-dried powder injection. 11. the preparation method of the Chinese medicine composition for the treatment of simple diastolic hypertension as claimed in claim 6, is characterized in that the method is: Chinese medicine composition adds conventional adjuvant, according to conventional technology, makes tablet, capsule, powder , pills, granules, honey refining ointment, controlled release preparation, oral liquid preparation or injection preparation. 12. the preparation method of the Chinese medicine composition for the treatment of isolated diastolic hypertension as claimed in claim 11, is characterized in that described capsule is soft capsule. 13. the preparation method of the Chinese medicine composition for the treatment of simple diastolic hypertension as claimed in claim 11, is characterized in that described pill is dripping pill or honeyed pill. 14. The preparation method of the Chinese medicine composition for treating isolated diastolic hypertension as claimed in claim 11, characterized in that the controlled-release preparation is a slow-release preparation or an immediate-release preparation. 15. The preparation method of the traditional Chinese medicine composition for treating isolated diastolic hypertension as claimed in claim 11, characterized in that the injection preparation is freeze-dried powder injection. 16. The application of the Chinese medicine composition as described in any one of claims 1-5 in the preparation of a medicament for treating isolated diastolic hypertension. 17. The application of the traditional Chinese medicine composition as described in any one of claims 1-5 in the preparation of medicines for improving blood lipid.